دورية أكاديمية
Future Directions for Developing Non-dopaminergic Strategies for the Treatment of Parkinson's Disease.
| العنوان: | Future Directions for Developing Non-dopaminergic Strategies for the Treatment of Parkinson's Disease. |
|---|---|
| المؤلفون: | van Wamelen DJ; Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom.; Department of Basic & Clinical Neuroscience, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom.; Parkinson Foundation Centre of Excellence at King's College Hospital NHS Foundation Trust, London, United Kingdom.; Department of Neurology, Centre of Expertise for Parkinson & Movement Disorders, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, the Netherlands., Leta V; Department of Basic & Clinical Neuroscience, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom.; Parkinson Foundation Centre of Excellence at King's College Hos- pital NHS Foundation Trust, London, United Kingdom.; Parkinson Foundation Centre of Excellence at King's College Hospital NHS Foundation Trust, London, United Kingdom., Chaudhuri KR; Department of Basic & Clinical Neuroscience, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom.; Parkinson Foundation Centre of Excellence at King's College Hospital NHS Foundation Trust, London, United Kingdom., Jenner P; School of Cancer & Pharmaceutical Sciences, Institute of Pharmaceutical Science, King's College London, London, United Kingdom. |
| المصدر: | Current neuropharmacology [Curr Neuropharmacol] 2024; Vol. 22 (10), pp. 1606-1620. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Bentham Science Publishers Country of Publication: United Arab Emirates NLM ID: 101157239 Publication Model: Print Cited Medium: Internet ISSN: 1875-6190 (Electronic) Linking ISSN: 1570159X NLM ISO Abbreviation: Curr Neuropharmacol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Sharjah, U.A.E. ; San Francisco, CA : Bentham Science Publishers, c2003- |
| مواضيع طبية MeSH: | Parkinson Disease*/drug therapy , Parkinson Disease*/metabolism , Antiparkinson Agents*/therapeutic use, Humans ; Animals |
| مستخلص: | The symptomatic treatment of Parkinson's disease (PD) has been dominated by the use of dopaminergic medication, but significant unmet need remains, much of which is related to non-motor symptoms and the involvement of non-dopaminergic transmitter systems. As such, little has changed in the past decades that has led to milestone advances in therapy and significantly improved treatment paradigms and patient outcomes, particularly in relation to symptoms unresponsive to levodopa. This review has looked at how pharmacological approaches to treatment are likely to develop in the near and distant future and will focus on two areas: 1) novel non-dopaminergic pharmacological strategies to control motor symptoms; and 2) novel non-dopaminergic approaches for the treatment of non-motor symptoms. The overall objective of this review is to use a 'crystal ball' approach to the future of drug discovery in PD and move away from the more traditional dopamine-based treatments. Here, we discuss promising non-dopaminergic and 'dirty drugs' that have the potential to become new key players in the field of Parkinson's disease treatment. (Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.) |
| References: | Nat Rev Neurosci. 2017 Aug;18(8):509. (PMID: 28720825) Parkinsonism Relat Disord. 2016 Jan;22 Suppl 1:S41-6. (PMID: 26459660) Brain Res. 2016 May 1;1638(Pt A):74-87. (PMID: 26423935) Expert Opin Drug Saf. 2019 Dec;18(12):1203-1218. (PMID: 31619083) Exp Toxicol Pathol. 2015 Feb;67(2):211-7. (PMID: 25547370) Arch Med Res. 2020 Oct;51(7):739-740. (PMID: 32571606) Transl Neurodegener. 2022 Oct 13;11(1):43. (PMID: 36229860) Front Neurosci. 2014 May 22;8:113. (PMID: 24904259) Brain Res. 1990 Feb 26;510(1):104-7. (PMID: 1691042) Parkinsonism Relat Disord. 2016 Nov;32:73-79. (PMID: 27632893) Front Aging Neurosci. 2022 Oct 20;14:1023574. (PMID: 36337703) J Neurol. 2000 Apr;247 Suppl 2:II43-50. (PMID: 10991665) Northwest Med. 1970 Aug;69(8):561-3. (PMID: 5459300) J Pharmacol Exp Ther. 2018 Dec;367(3):442-451. (PMID: 30291173) Cells. 2020 Oct 09;9(10):. (PMID: 33050305) J Pharmacol Exp Ther. 2009 Jul;330(1):294-303. (PMID: 19332567) Mov Disord. 2015 Jun;30(7):919-27. (PMID: 25737166) Mov Disord. 2015 Sep;30(10):1343-50. (PMID: 26094993) JAMA Neurol. 2015 Dec;72(12):1491-500. (PMID: 26523919) Parkinsonism Relat Disord. 2000 Apr 1;6(2):69-76. (PMID: 10699387) Prog Neurobiol. 2012 Jan;96(1):69-86. (PMID: 22075179) Nature. 2005 Oct 13;437(7061):942-3. (PMID: 16222266) Expert Opin Pharmacother. 2020 Dec;21(18):2279-2291. (PMID: 32804544) Mov Disord. 2020 Jun;35(6):1046-1054. (PMID: 32198802) Int Rev Neurobiol. 2017;132:33-54. (PMID: 28554413) Mov Disord. 2005 Sep;20(9):1133-42. (PMID: 15954133) Biochem Biophys Res Commun. 2013 Nov 1;440(4):664-70. (PMID: 24103762) NPJ Parkinsons Dis. 2022 Feb 21;8(1):17. (PMID: 35190544) Front Neurol. 2018 Sep 26;9:806. (PMID: 30319535) J Neural Transm (Vienna). 2017 Aug;124(8):1029-1036. (PMID: 28702850) Parkinsonism Relat Disord. 2020 Nov;80 Suppl 1:S7-S12. (PMID: 33349582) Ann Neurol. 2006 Apr;59(4):591-6. (PMID: 16566021) Lancet Neurol. 2006 Nov;5(11):974-83. (PMID: 17052664) Eur J Neurosci. 2019 Feb;49(3):384-398. (PMID: 30118169) Int Rev Neurobiol. 2017;133:557-583. (PMID: 28802933) Front Aging Neurosci. 2017 Sep 20;9:301. (PMID: 28979203) Cell Rep. 2022 Apr 19;39(3):110716. (PMID: 35443174) Clin Neuropharmacol. 1987 Jun;10(3):238-46. (PMID: 2900682) Neurochem Int. 2020 Nov;140:104844. (PMID: 32891683) Mov Disord. 2005 Aug;20(8):932-6. (PMID: 15791634) Eur J Neurosci. 2019 Jan;49(2):199-214. (PMID: 30326151) J Clin Invest. 2014 Mar;124(3):1340-9. (PMID: 24531549) Neuroepidemiology. 2018;51(3-4):190-206. (PMID: 30153669) J Parkinsons Dis. 2018;8(3):409-420. (PMID: 30056433) J Neuropsychiatry Clin Neurosci. 2002 Spring;14(2):223-36; discussion 222. (PMID: 11983801) J Parkinsons Dis. 2020;10(4):1389-1396. (PMID: 32716320) Mov Disord. 2020 May;35(5):900-901. (PMID: 32415717) Brain. 2015 Apr;138(Pt 4):829-30. (PMID: 25669729) Mov Disord. 2019 Mar;34(3):353-365. (PMID: 30719763) Neurology. 2017 Jun 6;88(23):2198-2206. (PMID: 28490648) Mar Drugs. 2019 Feb 10;17(2):. (PMID: 30744179) J Parkinsons Dis. 2020;10(4):1751-1761. (PMID: 32804101) J Neurol Sci. 2018 Mar 15;386:39-45. (PMID: 29406964) Cochrane Database Syst Rev. 2022 Jun 6;6:CD011574. (PMID: 35665915) Expert Rev Neurother. 2023 Jan;23(1):25-43. (PMID: 36701529) Nat Rev Drug Discov. 2018 Nov;17(11):804-822. (PMID: 30262889) Adv Neurol. 1987;45:1-18. (PMID: 3825687) Trans Am Neurol Assoc. 1969;94:85-90. (PMID: 4907453) Neurology. 1990 Oct;40(10):1529-34. (PMID: 2215943) CNS Drugs. 2014 May;28(5):455-74. (PMID: 24687255) Acta Neurol Scand. 2021 Jan;143(1):3-12. (PMID: 32813911) Eur J Neurol. 2023 Apr;30(4):1118-1134. (PMID: 36437702) Arch Neurol. 1969 Oct;21(4):343-54. (PMID: 5820999) Neuropharmacology. 2022 Jun 1;210:109027. (PMID: 35292330) NPJ Parkinsons Dis. 2017 Jan 25;3:5. (PMID: 28649605) Neurol Res. 2010 Nov;32(9):918-24. (PMID: 20887679) Behav Brain Res. 2015 Jan 15;277:136-45. (PMID: 25086269) CNS Drugs. 2012 Dec;26(12):1017-32. (PMID: 23114872) J Parkinsons Dis. 2022;12(8):2493-2506. (PMID: 36336941) Med J Aust. 2018 May 21;208(9):404-409. (PMID: 29764353) Trends Pharmacol Sci. 2005 Oct;26(10):511-6. (PMID: 16125796) Parkinsonism Relat Disord. 2021 Aug;89:186-194. (PMID: 34362670) Eur J Neurol. 2019 Mar;26(3):400-406. (PMID: 30175887) Neuropharmacology. 2020 Jun 15;170:108024. (PMID: 32142791) Int J Geriatr Psychiatry. 2015 Jan;30(1):46-54. (PMID: 24737460) Proc Natl Acad Sci U S A. 1987 Aug;84(16):5976-80. (PMID: 3475716) Mov Disord. 2004 Sep;19(9):1059-64. (PMID: 15372596) Brain. 2011 Apr;134(Pt 4):979-86. (PMID: 21371994) Front Neurol. 2022 May 17;13:880407. (PMID: 35655619) Expert Opin Investig Drugs. 2020 Nov;29(11):1249-1267. (PMID: 32853086) Mov Disord. 2015 Apr;30(4):510-6. (PMID: 25382161) Clin Chim Acta. 2021 Nov;522:114-126. (PMID: 34389279) Trends Neurosci. 2010 Sep;33(9):424-34. (PMID: 20561690) Neuropharmacology. 2018 Aug;138:304-314. (PMID: 29936243) Neurosci Res. 2017 Sep;122:45-50. (PMID: 28577977) Mov Disord. 2005 Aug;20(8):919-31. (PMID: 16007614) Sci Rep. 2021 Dec 8;11(1):23645. (PMID: 34880345) Int Rev Neurobiol. 2017;134:1493-1505. (PMID: 28805581) Mov Disord. 2018 Nov;33(11):1670-1672. (PMID: 30485909) Brain. 2019 Nov 1;142(11):3580-3591. (PMID: 31603207) Mov Disord. 2019 Feb;34(2):180-198. (PMID: 30653247) Parkinsonism Relat Disord. 2008;14 Suppl 2:S154-8. (PMID: 18579429) Chem Biol Interact. 2019 Sep 01;310:108757. (PMID: 31323226) Mov Disord. 2008 Sep 15;23(12):1641-52. (PMID: 18683238) Prog Brain Res. 2008;172:423-63. (PMID: 18772045) Mov Disord. 2011 Oct;26 Suppl 3:S42-80. (PMID: 22021174) Mov Disord. 2018 Nov;33(11):1769-1776. (PMID: 30387904) Drug Des Devel Ther. 2021 Jun 10;15:2507-2517. (PMID: 34140766) Front Neurol. 2014 May 20;5:78. (PMID: 24904522) Cold Spring Harb Perspect Med. 2011 Sep;1(1):a008862. (PMID: 22229124) Neuropharmacology. 2020 May 1;167:108006. (PMID: 32086070) Brain Behav. 2021 Oct;11(10):e2336. (PMID: 34478245) Sleep. 2012 May 01;35(5):713-5. (PMID: 22547898) Front Neurol. 2018 Dec 06;9:1041. (PMID: 30574117) Neurology. 2001 Nov 27;57(10):1829-34. (PMID: 11723272) Neurotox Res. 2009 Apr;15(3):246-51. (PMID: 19384597) Med Clin North Am. 1999 Mar;83(2):415-43, vi-vii. (PMID: 10093586) Curr Neuropharmacol. 2023;21(8):1786-1805. (PMID: 35293295) Clin Neuropharmacol. 1994 Feb;17(1):73-82. (PMID: 8149361) J Neural Transm (Vienna). 2017 Aug;124(8):907-914. (PMID: 28028643) Neuropharmacology. 2014 Feb;77:1-8. (PMID: 24067924) J Neurosci. 2021 Jul 28;41(30):6388-6414. (PMID: 34131032) Neurology. 1985 Apr;35(4):522-6. (PMID: 3982637) Sci Rep. 2019 Jan 28;9(1):797. (PMID: 30692568) Parkinsonism Relat Disord. 2021 Jun;87:25-31. (PMID: 33933853) Neurotherapeutics. 2020 Oct;17(4):1366-1377. (PMID: 32749651) Brain. 2010 Nov;133(11):3434-43. (PMID: 20884645) Behav Sci (Basel). 2021 Apr 17;11(4):. (PMID: 33920698) J Neurol Neurosurg Psychiatry. 2015 Feb;86(2):135-43. (PMID: 24828899) J Mol Neurosci. 2013 Nov;51(3):851-62. (PMID: 23943375) Sci Rep. 2021 May 5;11(1):9611. (PMID: 33953218) J Neurochem. 1993 Jan;60(1):197-203. (PMID: 8417140) Brain. 2017 Jul 1;140(7):1959-1976. (PMID: 28549077) Behav Brain Res. 2011 Aug 10;221(2):564-73. (PMID: 20060022) Brain. 2015 Mar;138(Pt 3):653-63. (PMID: 25539902) Front Pharmacol. 2022 Jun 01;13:861094. (PMID: 35721194) J Neural Transm (Vienna). 2019 Jun;126(6):699-710. (PMID: 31115669) J Neurol Neurosurg Psychiatry. 2018 Dec;89(12):1279-1287. (PMID: 30464029) Cureus. 2022 Sep 13;14(9):e29118. (PMID: 36259026) Parkinsonism Relat Disord. 2020 Nov;80 Suppl 1:S54-S63. (PMID: 33349581) Transl Psychiatry. 2017 Apr 11;7(4):e1088. (PMID: 28398338) Parkinsonism Relat Disord. 2020 Nov;80 Suppl 1:S21-S27. (PMID: 33349576) Adv Pharmacol. 2019;86:273-305. (PMID: 31378255) Trends Pharmacol Sci. 2019 Dec;40(12):1006-1020. (PMID: 31711626) Eur J Pharmacol. 2022 Jul 15;927:175070. (PMID: 35659968) Mov Disord Clin Pract. 2019 Feb 05;6(3):227-234. (PMID: 30949554) Diagnostics (Basel). 2020 May 25;10(5):. (PMID: 32466249) J Pers Med. 2021 Aug 07;11(8):. (PMID: 34442417) Parkinsonism Relat Disord. 2020 Nov;80 Suppl 1:S28-S36. (PMID: 33349577) Aging Dis. 2021 Jul 1;12(4):1021-1035. (PMID: 34221546) Behav Brain Res. 2023 May 8;445:114367. (PMID: 36863462) Mov Disord. 2010 Aug 15;25(11):1646-51. (PMID: 20629164) Int Rev Neurobiol. 2011;100:107-25. (PMID: 21971005) Front Neurosci. 2020 Dec 21;14:574652. (PMID: 33408605) Parkinsonism Relat Disord. 2013 May;19(5):508-14. (PMID: 23402994) Brain Pathol. 2011 Jul;21(4):419-27. (PMID: 21106039) J Parkinsons Dis. 2021;11(2):395-404. (PMID: 33682731) NPJ Parkinsons Dis. 2022 Mar 18;8(1):29. (PMID: 35304480) |
| فهرسة مساهمة: | Keywords: GABA.; Parkinson’s disease; acetylcholine; drug targets; non-dopaminergic; pharmacology; serotonin |
| المشرفين على المادة: | 0 (Antiparkinson Agents) |
| تواريخ الأحداث: | Date Created: 20230801 Date Completed: 20240613 Latest Revision: 20240731 |
| رمز التحديث: | 20240731 |
| مُعرف محوري في PubMed: | PMC11284721 |
| DOI: | 10.2174/1570159X21666230731110709 |
| PMID: | 37526188 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1875-6190 |
|---|---|
| DOI: | 10.2174/1570159X21666230731110709 |